Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102


Hacioglu M. B. , Kostek O., Kurt N., Kucukarda A., Gokyer A., Ustabasioglu F. E. , ...Daha Fazla

JOURNAL OF BUON, cilt.24, ss.2198-2204, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 24 Konu: 5
  • Basım Tarihi: 2019
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.2198-2204

Özet

Purpose: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments and prognostic significance in the patients with metastatic colorectal cancer (mCRC).